US$ 29.73
semaglutide pharmacokinetics For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg Effect of Semaglutide on the
Description
This is a common question for individuals using GLP-1 receptor agonists, a class of medications that mimic natural hormones to manage blood sugar and appetite

Personally, I think both perspectives miss the bigger picture

In this post, I take a deep dive into EVOKE and EVOKE+, examining trial design, endpoints, effect sizes, and interpretability

What Are the Cardiovascular Outcomes of Semaglutide in Patients With Type 2 Diabetes and Cardiovascular Disease

Lillys tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
